Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab long-term safety in psoriatic arthritis
NCT03347110Phase 2Completed
- Sponsor
- UCB
- Start
- Nov 2017
- Primary completion
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of bimekizumab in psoriatic arthritis (PsA), sponsored by UCB. Started Nov 2017; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03347110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03347110.